Show simple item record

dc.contributor.authorUrbano-Gámez, Jesús David
dc.contributor.authorGuzzi, Cinzia
dc.contributor.authorBernal, Manuel
dc.contributor.authorSolivera, Juan
dc.contributor.authorMartinez, Inigo Zubiavrre
dc.contributor.authorCaro, Carlos
dc.contributor.authorGarcía-Martín, María Luisa
dc.date.accessioned2024-10-03T11:10:08Z
dc.date.available2024-10-03T11:10:08Z
dc.date.issued2024-05-10
dc.description.abstractThe application of metal-based nanoparticles (mNPs) in cancer therapy and diagnostics (theranostics) has been a hot research topic since the early days of nanotechnology, becoming even more relevant in recent years. However, the clinical translation of this technology has been notably poor, with one of the main reasons being a lack of understanding of the disease and conceptual errors in the design of mNPs. Strikingly, throughout the reported studies to date on in vivo experiments, the concepts of “tumor targeting” and “tumor cell targeting” are often intertwined, particularly in the context of active targeting. These misconceptions may lead to design flaws, resulting in failed theranostic strategies. In the context of mNPs, tumor targeting can be described as the process by which mNPs reach the tumor mass (as a tissue), while tumor cell targeting refers to the specific interaction of mNPs with tumor cells once they have reached the tumor tissue. In this review, we conduct a critical analysis of key challenges that must be addressed for the successful targeting of either tumor tissue or cancer cells within the tumor tissue. Additionally, we explore essential features necessary for the smart design of theranostic mNPs, where ‘smart design’ refers to the process involving advanced consideration of the physicochemical features of the mNPs, targeting motifs, and physiological barriers that must be overcome for successful tumor targeting and/or tumor cell targeting.en_US
dc.identifier.citationUrbano-Gámez, Guzzi, Bernal, Solivera, Martinez, Caro, García-Martín. Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics. International Journal of Molecular Sciences. 2024;25(10)en_US
dc.identifier.cristinIDFRIDAID 2274396
dc.identifier.doi10.3390/ijms25105213
dc.identifier.issn1661-6596
dc.identifier.issn1422-0067
dc.identifier.urihttps://hdl.handle.net/10037/35027
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.journalInternational Journal of Molecular Sciences
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleTumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranosticsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)